CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are both growth hormone secretagogues, but they work through different receptor pathways. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog, while Ipamorelin is a growth hormone-releasing peptide (GHRP). They are frequently combined rather than used as alternatives.
Side-by-Side Comparison
| Category | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism of action | GHRH analog that binds to GHRH receptors on the pituitary gland, amplifying the natural GH release signal. The DAC (Drug Affinity Complex) version extends half-life to ~8 days by binding to albumin. | Selective GH secretagogue that mimics ghrelin at GHS-R1a receptors on the pituitary. Triggers a GH pulse without significantly raising cortisol, prolactin, or appetite (unlike other GHRPs). |
| Primary research area | Growth hormone deficiency, body composition improvement, anti-aging research. Studied for sustained GH elevation. | Clean GH release with minimal side effects. Studied for GH deficiency and body composition with a favorable safety profile compared to other GHRPs. |
| Evidence level | Phase II clinical trials completed (ConjuChem). Published human pharmacokinetic data showing sustained GH/IGF-1 elevation. Not FDA-approved. | Phase II clinical trials completed. Published human data demonstrating selective GH release without cortisol/prolactin spikes. Not FDA-approved. |
| Administration route | Subcutaneous injection. DAC version: once weekly. No-DAC version: 1-3 times daily. | Subcutaneous injection, typically 1-3 times daily, often before bed. |
| Typical research dosing | DAC version: 2 mg once weekly. No-DAC version: 100 mcg 1-3x daily. | 100-300 mcg subcutaneous, 1-3 times daily. Often dosed before bed to augment natural GH pulse. |
| Key studies/evidence | Teichman et al. (2006) — human PK study showing sustained IGF-1 elevation for 6+ days with DAC version. ConjuChem phase II data on body composition. | Raun et al. (1998) — selective GH release in animal models. Human studies confirming GH release without cortisol/prolactin elevation. Phase II trials for growth hormone deficiency. |
Can They Be Stacked?
This is the most widely used GH peptide combination. The GHRH analog (CJC-1295) amplifies the signal while the GHRP (Ipamorelin) triggers the pulse, producing synergistic GH release that research suggests is 3-10x greater than either alone. Human pharmacokinetic data supports the combination rationale.
Verdict
These peptides are more complementary than competitive. CJC-1295 provides the sustained GHRH signal that "primes" the pituitary, while Ipamorelin provides the trigger for clean GH pulses. If choosing one, Ipamorelin offers a cleaner side-effect profile (no cortisol/prolactin spikes), while CJC-1295 DAC offers convenience with weekly dosing.
Related Comparisons
MK-677 (Ibutamoren) and CJC-1295 both elevate growth hormone levels, but through entirely different mechanisms and routes. MK-677 is technically not a peptide -- it's a non-peptide ghrelin mimetic taken orally. CJC-1295 is a GHRH analog that requires injection. This distinction significantly affects their use profiles.
CJC-1295 vs SermorelinCJC-1295 and Sermorelin are both GHRH analogs that stimulate growth hormone release through the same receptor pathway. The key difference is that Sermorelin was the first GHRH analog with decades of clinical use, while CJC-1295 is a newer modified version designed for a much longer half-life.
Ipamorelin vs MK-677Ipamorelin and MK-677 both stimulate growth hormone release through ghrelin-related pathways, but with important differences in selectivity and side effect profiles. Ipamorelin is a true peptide requiring injection, while MK-677 is a non-peptide small molecule taken orally.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.